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progenitor population that directs SG
turnover and sebocyte differentiation
(Horsley et al., 2006). However, our
high-resolution 3D data reveal that
BLIMP1 is expressed throughout the
HF in both quiescent and differentiated
HF cells and sebocytes. Furthermore,
BLIMP1þ cells located near or in the
SG were not found to be LRCs. This
finding supports a more recent study,
which found BLIMP1 in mature sebo-
cytes, (Sellheyer and Krahl, 2010),
raising important questions about the
role of BLIMP1 and the true identity of
sebocyte progenitor cells. The discovery
of a slow-cycling population offers
unprecedented insights into MG cell
turnover and may shed light on MG
age–related atrophy and dry eye disease.
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TO THE EDITOR
Over forty-one genetic susceptibility
loci of genome-wide significance
(Po5 108) are known for psoriasis,
a common complex genetic disease
characterized by epidermal hyperproli-
feration and cutaneous inflammation.
The most strongly associated of these
loci maps to the HLA-C gene in the
major histocompatibility complex
(MHC) on chromosome 6p21.3 (Zhang
et al., 2009; Tsoi et al., 2012). Recent
fine-mapping studies have identified
multiple independent association signals
in the MHC, and the strongest signal is
associated with HLA-C*06:02 (previous
designations: HLA-Cw6, HLA-Cw*0602)
or single-nucleotide polymorphisms
(SNPs) that are near-perfect surrogates
for this allele (Feng et al., 2009; Knight
et al., 2012; Das et al., 2014; Okada
et al., 2014). HLA-C*06:02 has been
known to be psoriasis-associated since
the 1970s, and most of the world
populations that have been studied
have shown strong evidence of asso-
ciation (Zhang et al., 2009; Stuart et al.,
2010; Shaiq et al., 2013; Okada et al.,
2014). Yet, it is difficult to perform a
routine affordable laboratory test for the
presence or absence of HLA-C*06:02,
because DNA-based testing is compli-
cated both by the high degree of
polymorphism of HLA-C (2375 alleles
encoding 1677 protein variations; July
2014 release of IMGT/HLA database;
Robinson et al., 2013) and by the
sequence similarity of HLA-C*06:02 to
other HLA-C as well as HLA-A and HLA-
B alleles. We previously used a seven-
SNP genotyping system to unam-
biguously define HLA-C*06:02 and
several other HLA-C alleles (Nair et al.,
2006). Others have used allele-specific
amplification followed by electro-
phoresis (Bunce et al., 1995), PCR
amplification followed by restriction
enzyme digestion (Tazi Ahnini et al.,
1999), a combination of four surrogate
SNPs that are amenable to Taqman
genotyping (Nikamo and Stahle, 2012),
and a three-SNP haplotype (rs1576-
rs130076-rs2523619) known to be in
strong linkage disequilibrium (LD) with
HLA-C*06:02 (Huffmeier et al., 2009).
Imputation of classical HLA alleles inclu-Accepted article preview online 10 December 2014; published online 8 January 2015
Abbreviations: LD, linkage disequilibrium; MHC, major histocompatibility complex; SNP, single-
nucleotide polymorphism
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ding HLA-C*06:02 is another widely
used approach (Leslie et al., 2008; Jia
et al., 2013), but this requires high-
density genotyping of the sample for
SNPs throughout the MHC region, as
well as a reference panel drawn from
the same population that has been typed
for both classical HLA genes and a high
density of MHC SNPs.
During the course of our genome-
wide association studies of psoriasis
and fine mapping of MHC loci, we
discovered that the A allele of SNP
rs4406273, located 28.73 kb centro-
meric of HLA-C, is a near-perfect surro-
gate for HLA-C*06:02. Notably, this
SNP was the most strongly associated
variant in the largest genome-wide asso-
ciation study of psoriasis to date (Tsoi
et al., 2012). As rs4406273 is only 3
bases away from another SNP, it is not
amenable to the commonly used
Taqman (Applied Biosystems, Foster
City, CA) genotyping assay design.
However, it can be genotyped using
single-base extension methods. In this
study, we examined the adequacy
of genotyping rs4406273 as a single
marker surrogate for HLA-C*06:02 in
three different populations—5,009 Eur-
opean-ancestry samples collected in
Michigan, 835 samples from Pakistan,
and 307 samples from Thailand. All the
DNA samples used in this study were
prepared from peripheral blood
obtained following protocols approved
by the ethics boards of participating
institutions and adhering to the Declara-
tion of Helsinki principles. Written
informed consent was obtained
from all study participants. Reference
HLA-C*06:02 genotypes were gene-
rated by our previously reported
seven-marker method (Nair et al.,
2006), and rs4406273 was genotyped
using the single-base extension method
Table 1. Performance of the rs4406273-A allele as a surrogate for HLA-C*06:02
Variable Michigan sample Pakistan sample Thailand sample
(10,018 alleles) (1,670 alleles) (614 alleles)
Frequency HLA-C*06:02 0.1624 (0.1553–0.1698)1 0.1725 (0.1551–0.1913) 0.1303 (0.1060–0.1592)
Frequency rs4406273-A 0.1612 (0.1541–0.1685) 0.1683 (0.1511–0.1870) 0.1336 (0.1089–0.1628)
D0 measure of LD 0.9963 (0.9927–0.9993) 0.9870 (0.9710–1.0000) 1.0000 (1.0000–1.0000)
r2 measure of LD 0.9839 (0.9769–0.9903) 0.9456 (0.9150–0.9722) 0.9706 (0.9255–1.0000)
Genotype concordance 0.9956 (0.9934–0.9971) 0.9844 (0.9736–0.9909) 0.9935 (0.9766–0.9988)
Sensitivity 0.9896 (0.9833–0.9935) 0.9653 (0.9373–0.9810) 1.0000 (0.9542–1.0000)
Specificity 0.9994 (0.9986–0.9997) 0.9978 (0.9936–0.9994) 0.9963 (0.9864–0.9993)
PPV 0.9969 (0.9928–0.9987) 0.9893 (0.9691–0.9971) 0.9756 (0.9154–0.9957)
NPV 0.9980 (0.9968–0.9987) 0.9928 (0.9868–0.9961) 1.0000 (0.9928–1.0000)
Accuracy 0.9978 (0.9967–0.9985) 0.9922 (0.9867–0.9954) 0.9967 (0.9882–0.9994)
MCC 0.9919 (0.9885–0.9953) 0.9726 (0.9579–0.9875) 0.9859 (0.9667–1.0000)
Abbreviations: LD, linkage disequilibrium; MCC, Matthews correlation coefficient; NPV, negative predictive value; PPV, positive predictive value.
195% confidence intervals shown in parentheses for all values.
Table 2A. Comparison of the association of HLA-C*06:02 and rs4406273-A with psoriasis for samples successfully
typed for both markers
HLA-C*06:02 rs4406273-A
Allele frequency Allele frequency
Cohort n Cases Controls OR P-value Cases Controls OR P-value
Michigan 5009 0.2327 0.0900 3.41 8.5 10 83 0.2307 0.0896 3.38 1.8 10 81
Pakistan 835 0.2484 0.1257 2.42 1.8 10 10 0.2390 0.1248 2.32 1.6109
Thailand 307 0.1766 0.0425 5.38 7.5106 0.1791 0.0472 4.91 1.0105
Abbreviation: OR, odds ratio.
Table 2 B. Conditional haplotype testing of independent effects for samples
successfully typed for both HLA-C*06:02 and rs4406273
Test marker Conditioning marker
Independent effects P-value
Michigan Pakistan Thailand
HLA-C*06:02 rs4406273 0.0052 0.011 0.20
rs4406273 HLA-C*06:02 0.20 0.11 0.82
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implemented in the Applied Biosystems
Snapshot Assay. Briefly, this assay
involved (1) amplification of a 237-bp
segment of DNA encompassing
rs4406273 using PCR primers 50-CTG
GAAAGGGTGAGGAAACA-30 and 50-
TGACCTCCCTACTGCAGCTT-30, (2) in-
activation of unused primers and
deoxynucleotide triphosphates by
treatment with a mixture of shrimp
alkaline phosphatase and exonuclease,
(3) performing the primer extension
reaction using an aliquot of the PCR
product and probe GAGCCTCAGAAG
AAATGCAGCTSTGAC that would be
extended by one base corresponding to
the allele(s) of rs4406273 (A and/or G),
(4) inactivation of the unused probe by
treatment with alkaline phosphatase,
and (5) identification of the added base
by electrophoresis on an Applied
Biosystems capillary electrophoresis
apparatus using LIZ120 size standard
ladder (Applied Biosystems).
The utility of the rs4406273-A allele
as a surrogate for HLA-C*06:02 was ass-
essed using various metrics (Table 1).
Allele frequencies were very similar in
all three cohorts, with the A allele of
rs4406273 slightly less abundant in the
Michigan and Pakistani samples and
slightly more abundant in the Thai sam-
ple than HLA-C*06:02. LD between the
two variants, as measured by the D0 and
r2 coefficients, was 0.95 or greater in all
three samples. Genotype concordances
were also uniformly high (0.984–0.996).
The correspondence of cross-classified
allele counts for the rs4406273-A and C
alleles on one hand and HLA-C*06:02
and non-C*06:02 alleles on the other
hand was also assessed by six different
measures for the performance of a binary
classification test—sensitivity, specificity,
positive predictive value, negative pre-
dictive value, accuracy, and the Mat-
thews correlation coefficient (Matthews,
1975), which is the Pearson correlation
coefficient between two binary
classifications. Values for these
performance measures were very high,
ranging from 0.990 to 0.999 for the
Michigan sample, from 0.965 to 0.998
for the Pakistani sample, and from 0.976
to 1.000 for the Thai sample.
In Table 2A, we compare the results
of a logistic regression test for associa-
tion between psoriasis and dosage of the
HLA-C*06:02 and rs4406273-A alleles.
In all three cohorts, the odds ratio
estimates and P values for rs4406273
are slightly conservative compared with
those of HLA-C*06:02, suggesting that
this marker is unlikely to yield false
positive results. Conditional haplotype
testing of independent effects (Table 2B)
shows that residual effects after condi-
tioning are negligible compared with
the association P values.
We also assessed the performance
of rs4406273 as a surrogate for 928
individuals from 13 different populations
in phase 1 of the 1000 Genomes Project
(Abecasis et al., 2012) for which
sequence-based genotypes of HLA-C and
rs4406273 were available (Gourraud
et al., 2014); ftp://ftp.1000genomes.ebi.ac.
uk/vol1/ftp/technical/working/20140725_
hla_genotypes/ and ftp://ftp-trace.ncbi.nih.
gov/1000genomes/ftp/release/20110521/).
LD was very strong between rs4406273
and HLA-C*06:02 in four populations
of European descent from the United
States, Finland, Great Britain, and Italy
(r2¼0.984), and in three Asian popula-
tions from Japan and China (r2¼1.000).
LD values were somewhat lower but still
strong in two African populations from
Nigeria and Kenya (r2¼0.929) and in
four American populations from Puerto
Rico, Colombia, and the United States
(r2¼0.909).
The results presented here demon-
strate that genotyping rs4406273 can
be used as an excellent substitute for
more elaborate and expensive geno-
typing of HLA-C*06:02 in people of
European, Pakistani, Thai, Chinese, or
Japanese ancestry. This SNP may also be
a serviceable surrogate for HLA-C*06:02
in some African and American popula-
tions. Caution is warranted, however,
when applying this method to genetic
isolates or more distantly related popu-
lations. Although not amenable to the
popular Taqman assay owing to the
presence of proximal SNPs, any method
using primer extension can be used to
genotype rs4406273. For high-through-
put genotyping projects using commer-
cial microarrays, this SNP can be added
on as a custom marker if it is not already
present as part of the standard set.
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TO THE EDITOR
The article ‘‘Killing two birds with one
stone: oral tofacitinib reverses alopecia
universalis in a patient with plaque
psoriasis’’ by Craiglow and King
reported on the successful treatment of
a patient suffering from both psoriasis
and alopecia areata (Craiglow and King,
2014). The authors observed that before
treatment ‘‘the only prominent hair
growth on the scalp was within areas
of psoriasis (Craiglow and King, 2014).’’
This interesting clinical finding of
exclusion or withdrawal of one
inflammatory condition in the presence
of another has been previously noted
and has been described as a reverse
Ko¨bner reaction or Renbo¨k phenome-
non. The term Renbo¨k was first coined
by Happle in 1991 in an article des-
cribing three patients with an exclusion
of alopecia areata (hair growth) in areas
of seborrheic dermatitis or psoriasis
(Happle et al., 1991).
It has been suggested that the Renbo¨k
phenomen occurs as a result of different
T-helper (Th) inflammatory subsets (Th1,
Th2, Th17) amplifying self-sustaining
cytokines while suppressing alternative
pathways (Harris et al., 2010).
Thus, in a plaque of psoriasis, Th17
inflammatory cytokines may polarize
and recruit T cells to a singular
purpose over the exclusion of Th1
inflammatory pathways that occur in
alopecia areata (Harris et al., 2010).
The fact that various targeted bio-
logical treatments such as blockers of
tumor necrosis factor, T-cell surface
receptors, and ILs have been successful
in treating psoriasis but not alopecia
areata seemed to substantiate the
concept that the inflammatory subsets
in these two conditions were distinct.
However, the recent discovery that IL15
has a critical role in the pathogenesis of
alopecia areata (Xing et al., 2014) has
lead to the identification of a shared
pathway that can be targeted by a single
drug. The use of Janus kinase inhibitors
that block IL15 signaling appear to be a
promising therapy for patients with
alopecia areata and/or psoriasis
(Craiglow and King, 2014; Xing et al.,
2014). After treatment with tofacitinib,
the Renbo¨k phenomenon noted in this
case report resolved (Craiglow and King,
2014). The hair regrowth and resolution
of psoriasis suggest that the inflam-
matory pathways that were perpetua-
ting disease, as well as those leading
to exclusion or cross-regulation, were
either suppressed or normalized. A
further understanding of the mech-
anisms leading to the Renbo¨k pheno-
menon will hopefully provide insights
into the nuances and complex orche-
strations of the inflammatory pathways
seen in alopecia areata and psoriasis.
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